Loading...
A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Patients with Advanced Breast Cancer After First‐Line Chemotherapy
LESSONS LEARNED: Fulvestrant 500 mg maintenance therapy showed a clinical benefit rate of 76% and median progression‐free survival of 16.1 months in patients who achieved objective responses or disease control after first‐line chemotherapy. Adverse events with fulvestrant maintenance therapy were co...
Na minha lista:
| Udgivet i: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley & Sons, Inc.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8100565/ https://ncbi.nlm.nih.gov/pubmed/33245164 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13614 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|